GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Gross-Profit-to-Asset %

Ablynx NV (XBRU:ABLXS) Gross-Profit-to-Asset % : 13.37% (As of Dec. 2017)


View and export this data going back to . Start your Free Trial

What is Ablynx NV Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Ablynx NV's annualized Gross Profit for the quarter that ended in Dec. 2017 was €41.79 Mil. Ablynx NV's average Total Assets over the quarter that ended in Dec. 2017 was €312.54 Mil. Therefore, Ablynx NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2017 was 13.37%.


Ablynx NV Gross-Profit-to-Asset % Historical Data

The historical data trend for Ablynx NV's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Gross-Profit-to-Asset % Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.03 -2.92 -2.69 -5.98 16.92

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.04 36.60 21.76 27.62 13.37

Competitive Comparison of Ablynx NV's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Ablynx NV's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ablynx NV's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Ablynx NV's Gross-Profit-to-Asset % falls into.



Ablynx NV Gross-Profit-to-Asset % Calculation

Ablynx NV's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2017 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2017 )/( (Total Assets (A: Dec. 2016 )+Total Assets (A: Dec. 2017 ))/ count )
=55.562/( (266.764+389.848)/ 2 )
=55.562/328.306
=16.92 %

Ablynx NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2017 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2017 )/( (Total Assets (Q: Jun. 2017 )+Total Assets (Q: Dec. 2017 ))/ count )
=41.794/( (235.24+389.848)/ 2 )
=41.794/312.544
=13.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2017) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Ablynx NV Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ablynx NV Business Description

Traded in Other Exchanges
N/A
Address
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV Headlines

No Headlines